Quite an in depth review on CHF...

Quite an in depth review on CHF https://link.springer.com/article/10.1007/s40273-020-00952-0

Data from the USA 2014-2020
Some key takeaways...

Get With The Guidelines-Heart Failure, linked to Medicare data, reported 5-year mortality rates of 75.4%

In the USA, the estimated 2020 prevalence of HF is 6.9 million and is expected to increase by 24% to nearly 8.5 million in 2030

In the USA, the total cost of care (direct and indirect costs) for HF in 2020 is estimated at $43.6 billion, with over 70% of costs attributed to medical costs [3]. Without improvements in outcomes, the annual total cost of care in the USA is projected to increase to $69.7 billion by 2030 [3].



Why is that important????????


The data that MSB has released, included a 60% reduction in death from cardiac causes when treated at the earlier class 2 CHF stage. ( around 250 patients over 5 years followup)

That is the equivalent of lowering the 75.4% mortality, down to 30%.

Remember these results are ontop of current best practice possible.

Wow..... who wouldn't sign up for that given the extremely good safety profile, and unprecedented reduction in mortality, and the robustness of a 5 year placebo cobtrolled double blind "gold standard" trial. That actually hit the "gold standard" end point of mortality reduction...... which in the FDA's own words " is hard to ignore "